Search

Displaying results 3831 - 3840 of 7063 in total
  1. Drug

    Plasminogen

    go.drugbank.com/drugs/DB16701
    ApprovedInvestigational

    [A236035] This pathway is activated when a clot is no longer needed or to prevent a clot from extending beyond the site of injury. … Plasminogen is a pro-enzyme (i.e. a zymogen) which is cleaved to form plasmin - also known as [fibrinolysin] - as part of the fibrinolytic pathway that breaks down fibrin blood clots.

  2. Drug

    Teprotumumab

    go.drugbank.com/drugs/DB06343
    ApprovedInvestigational

    approved by the FDA in January 2020 for the treatment of TED. … [L11359] Following a clinical trial in which its efficacy in the treatment of thyroid eye disease (TED) was assessed, it received "breakthrough therapy" designation from the FDA in 2016[A190129] and was

  3. Drug

    Cobicistat

    go.drugbank.com/drugs/DB09065
    ApprovedInvestigational

    Although it does not have any anti-HIV activity, cobicistat acts as a pharmacokinetic enhancer by inhibiting cytochrome P450 3A isoforms (CYP3A) and therefore increases the systemic exposure of coadministered … Increasing systemic exposure of anti-retrovirals (ARVs) without increasing dosage allows for better treatment outcomes and a decreased side effect profile.

  4. Drug

    Lixisenatide

    go.drugbank.com/drugs/DB09265
    ApprovedInvestigational

    [L764] Adlyxin recieved FDA approval July 28, 2016.[L763] … Lixisenatide is a glucagon-like peptide-1 (GLP-1) receptor agonist used in the treatment of type II diabetes mellitus (T2DM).

    Mixtures: Soliqua SoloStar 100units/mL+33mcg/mL solution for injection in a pre-filled pen, SOLIQUA SOLUTION FOR INJECTION IN A PRE-FILLED PEN 100UNITS/ML + 50MCG/ML
  5. Drug

    Cerivastatin

    go.drugbank.com/drugs/DB00439
    ApprovedWithdrawn

    Food and Drug Administration (FDA) announced that Bayer Pharmaceutical Division voluntarily withdrew Baycol from the U.S. market, due to reports of fatal rhabdomyolysis, a severe adverse reaction from

  6. Drug

    Interferon alfa-2b

    go.drugbank.com/drugs/DB00105
    ApprovedInvestigational

    A type I interferon consisting of 165 amino acid residues with arginine in position 23. This protein is produced by recombinant DNA technology and resembles interferon secreted by leukocytes.

    Mixtures: Intron A, Intron ASynonyms: Intron A, Intron A (Interferon α2b)
  7. Drug

    Elbimilast

    go.drugbank.com/drugs/DB20663
    Investigational

    Elbimilast has a monoisotopic molecular weight of 442.04 Da. … Elbimilast is a small molecule drug. The usage of the INN stem '-milast' in the name indicates that Elbimilast is a Phosphodiesterase-4 (PDE4) inhibitor.

  8. Drug

    Atrasentan

    go.drugbank.com/drugs/DB06199
    ApprovedInvestigational

    Atrasentan is a novel, selective endothelin A receptor antagonist (SERA). … [L52855] In April 2025, atrasentan was granted accelerated approval by the FDA for the reduction of proteinuria in patients with primary IgA nephropathy, becoming the first endothelin A receptor antagonist

    Categories: Endothelin A Receptor Antagonists
  9. Drug

    Altanserin

    go.drugbank.com/drugs/DB19972
    Investigational

    Altanserin has a monoisotopic molecular weight of 411.14 Da. … Altanserin is a small molecule drug. The usage of the INN stem '-anserin' in the name indicates that Altanserin is a serotonin receptor antagonist.

    Categories: Compounds used in a research, industrial, or household setting
  10. Drug

    Vicasinabin

    go.drugbank.com/drugs/DB21587
    Investigational

    Vicasinabin has a monoisotopic molecular weight of 358.2 Da. … Vicasinabin is a small molecule drug.